Drug
Imaradenant clinical trials
Also written AZD4635.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses imaradenant is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy VolunteersCompletedPhase 1AstraZenecaNCT04478513Written as AZD4635
- A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid MalignanciesCompletedPhase 1AstraZenecaNCT03980821Written as AZD4635
- AZD4635 Relative Bioavailability StudyCompletedPhase 1AstraZenecaNCT03710434Written as AZD4635 50 mg nano-suspension (reference)
Given in every arm · 4 — imaradenant is usual care beside what is tested
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination StudyActive, not recruitingPhase 1/2MedImmune LLCNCT03381274Written as AZD4635
- An Open-label, Phase II Study of AZD4635 in Patients With Prostate CancerCompletedPhase 2AstraZenecaNCT04089553Written as AZD4635
- A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.CompletedPhase 2AstraZenecaNCT04495179Written as AZD4635
- A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid MalignanciesCompletedPhase 1AstraZenecaNCT02740985Written as AZD4635
Codes
What other systems call imaradenant · ClinicalTrials.gg INT015415
- UNII (FDA) 770140J08AIMARADENANTOne source FDA
- NCI Thesaurus C148039ImaradenantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 770140J08A | IMARADENANT | One source FDA |
| NCI Thesaurus | C148039 | Imaradenant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.